5-chloro-6-methoxy-3,4-dihydro-1(2H)-naphthalenone | 26231-22-1

• 分子结构分类: 有机化合物 - 苯类化合物 - 四氢化萘
• 英文名称: 5-chloro-6-methoxy-3,4-dihydro-1(2H)-naphthalenone
• 英文别名: 5-chloro-6-methoxy-3,4-dihydronaphtalen-1(2H)-one；7-methoxy-8-chloro-4-tetralone；5-chloro-6-methoxy-1,2,3,4-tetrahydro-1-naphthalenone；5-chloro-6-methoxy-3,4-dihydronaphthalene-1(2H)-one；5-chloro-6-methoxy-3,4-dihydronapthalen-1(2H)-one；5-chloro-6-methoxy-1-tetralone；5-chloro-6-methoxy-3,4-dihydro-2H-naphthalen-1-one
• CAS: 26231-22-1
• 化学式: C₁₁H₁₁ClO₂
• 分子量: 210.66
• InChiKey: IBVLQEIGMLJFFO-UHFFFAOYSA-N

物化性质

• 熔点：
  134-135 °C(Solv: methanol (67-56-1))
• 沸点：
  360.6±42.0 °C(Predicted)
• 密度：
  1.248±0.06 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  2.6
• 重原子数：
  14
• 可旋转键数：
  1
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.36
• 拓扑面积：
  26.3
• 氢给体数：
  0
• 氢受体数：
  2

反应信息

• 作为反应物：
  描述：

  5-chloro-6-methoxy-3,4-dihydro-1(2H)-naphthalenone 在 sodium ethanolate 、 sodium hydroxide 、 三氯氧磷 作用下， 以 四氢呋喃 、 水 为溶剂， 生成 6-chloro-7-methoxy-4,5-dihydronaphtho[1,2-b]thiophene-2-carboxylic acid
  参考文献：
  名称：

  4H-Thieno[3,2-c]chromene based inhibitors of Notum Pectinacetylesterase

  摘要：

  A group of small molecule thienochromenes inhibitors of Notum Pectinacetylesterase are described. We developed SAR on three series based on carbon, oxygen and sulfur replacement of the 5-position. In each series, highly potent Notum Pectinacetylesterase inhibitors were identified. (C) 2016 Elsevier Ltd. All rights reserved.

  DOI：

  10.1016/j.bmcl.2016.01.038
• 作为产物：
  描述：

  5-amino-6-methoxy-3,4-dihydro-1(2H)-naphthalenone 在 copper(l) chloride 、 sodium nitrite 作用下， 生成 5-chloro-6-methoxy-3,4-dihydro-1(2H)-naphthalenone
  参考文献：
  名称：

  Synthesis of 2-(N-substituted amino)-6-hydroxy-1,2,3,4-tetrahydronaphthalen-1-ol derivatives.

  摘要：

  trans-6-羟基-2-(1-甲基-3-苯基丙基)氨基-1,2,3,4-四氢萘-1-醇(8a)、trans-6-羟基-2-(1-甲基-2-苯氧乙基)氨基-1,2,3,4-四氢萘-1-醇(8b)和trans-1,6-二羟基-2-(1-甲基-3-苯基丙基)氨基-1,2,3,4-四氢萘-5-羧酰胺(9a)作为我们寻找有用的心血管药物的一部分被合成。通过从3,4-二氢-1(2H)-萘满酮衍生物(36)开始，经过五步反应序列，制备了在萘环的5-、6-和7-位具有各种取代基的2-(N-取代氨基)-6-烷氧基-1,2,3,4-四氢萘-1-醇(10-31)。此外，2-(N-取代氨基)-1-茚醇衍生物(33)和6-(N-取代氨基)-2-羟基-6,7,8,9-四氢-5H-苯并环庚烯-5-醇(34,35)是通过相应的氨基醇与羰基化合物的还原烷基化获得的。这些N-取代的氨基醇(8-35)在麻醉犬中测试了其血管舒张活性，并在离体的豚鼠心房制备中测试了其β-阻断活性。

  DOI：

  10.1248/cpb.31.2329

文献信息

• 4H-THIENO[3,2-C]CHROMENE-BASED INHIBITORS OF NOTUM PECTINACETYLESTERASE AND METHODS OF THEIR USE
  申请人：BARBOSA Joseph

  公开号：US20120302562A1

  公开（公告）日：2012-11-29

  Compounds that may be used to inhibit Notum Pectinacetylesterase are described, as well as compositions comprising them, and methods of their use to treat diseases and disorders affecting bone.

  描述了可以用来抑制Notum果胶乙酰酯酶的化合物，以及包含它们的组合物，以及它们用于治疗影响骨骼的疾病和紊乱的方法。
• [EN] BACTERIOCHLORIN IMIDES<br/>[FR] IMIDES DE BACTÉRIOCHLORINES
  申请人：UNIV NORTH CAROLINA STATE

  公开号：WO2012166792A1

  公开（公告）日：2012-12-06

  Compound of Formula I: are described, along with compositions containing the same and methods of use thereof.

  化合物I的化学式：已经描述，并且描述了含有该化合物的组合物以及使用方法。
• Adrenergic amidines
  申请人：Abbott Laboratories

  公开号：US04634705A1

  公开（公告）日：1987-01-06

  Disclosed herein are adrenergic compounds represented by the formula ##STR1## wherein m is 0, 1 or 2; R.sub.1, R.sub.2, R.sub.3 and R.sub.7 are taken from the group consisting of hydrogen, hydroxy, loweralkyl, loweralkoxy, halo, amino, acetamido or NHSO.sub.2 R wherein R is taken from the group consisting of hydrogen or loweralkyl, provided that R.sub.1, R.sub.2, R.sub.3 and R.sub.7 cannot simultaneously be hydrogen or halo, and provided that when one of R.sub.1, R.sub.2, R.sub.3 and R.sub.7 is halo, the others cannot simultaneously be hydrogen and when two of R.sub.1, R.sub.2, R.sub.3 and R.sub.7 are halo, the other two cannot simultaneously be hydrogen and provided that R.sub.1 and R.sub.7 cannot simultaneously be methoxy each when R.sub.2 and R.sub.3 are hydrogen; R.sub.1 and R.sub.2 or R.sub.2 and R.sub.3 or R.sub.3 and R.sub.7 taken together can form a methylenedioxy or ethylenedioxy bridge; or R.sub.1 and R.sub.2 or R.sub.2 and R.sub.3 or R.sub.3 and R.sub.7 taken together with the aromatic ring can form a benzimidazole or indole bridge; and R.sub.4 and R.sub.5 are hydrogen or taken together form a closed ring of the formula ##STR2## wherein n is 1 or 2, and the combined solid and dashed line represents a single or double bond when n is 1, and R.sub.6 is taken from the group consisting of hydrogen or loweralkyl, and the pharmaceutically acceptable salts thereof.

  本公开涉及的肾上腺素类化合物由以下式表示：其中m为0、1或2；R.sub.1、R.sub.2、R.sub.3和R.sub.7取自氢、羟基、较低烷基、较低烷氧基、卤素、氨基、乙酰胺基或NHSO.sub.2 R的群，其中R取自氢或较低烷基，但要求R.sub.1、R.sub.2、R.sub.3和R.sub.7不能同时为氢或卤素，且当R.sub.1、R.sub.2、R.sub.3和R.sub.7中的一个为卤素时，其他的不能同时为氢，当R.sub.1、R.sub.2、R.sub.3和R.sub.7中有两个为卤素时，其他两个不能同时为氢，而且当R.sub.1和R.sub.7同时为甲氧基时，R.sub.2和R.sub.3为氢；R.sub.1和R.sub.2或R.sub.2和R.sub.3或R.sub.3和R.sub.7结合在一起可以形成甲二氧基或乙二氧基桥；或者R.sub.1和R.sub.2或R.sub.2和R.sub.3或R.sub.3和R.sub.7与芳香环结合在一起可以形成苯并咪唑或吲哚桥；R.sub.4和R.sub.5为氢或结合在一起形成下式的闭环：其中n为1或2，组合的实线和虚线代表单键或双键，当n为1时，R.sub.6取自氢或较低烷基，以及其药用可接受的盐。
• Aminoalkyl dihydronaphthalenes
  申请人：Abbott Laboratories

  公开号：US04473586A1

  公开（公告）日：1984-09-25

  Disclosed herein are 1-aminoalkyl-3,4-dihydronaphthalenes represented by the formula ##STR1## wherein n is 1 or 2; R, R.sub.1, and R.sub.2 are independently selected from hydrogen, hydroxy, loweralkoxy of 1 to 3 carbon atoms, loweralkenyloxy of 1 to 3 carbon atoms, thiomethyl, halo, or ##STR2## wherein R.sub.5 and R.sub.6 are independently selected from hydrogen, loweracyl of 1 to 4 carbon atoms or sulfonyl of the formula ##STR3## wherein R.sub.7 is loweralkyl of 1 to 4 carbon atoms; or R and R.sub.1, or R.sub.1 and R.sub.2 can be taken together to form a methylenedioxy or ethylenedioxy bridge; with the proviso that at least one of R, R.sub.1 or R.sub.2 must be other than hydrogen; and R.sub.3 and R.sub.4 are independently selected from hydrogen; loweralkyl of 1 to 4 carbon atoms; halo-substituted loweralkyl of 1 to 4 carbon atoms; arylalkyl of the formula ##STR4## wherein m is 0, 1 or 2, p is 0 or 1, R.sub.8 is hydrogen or loweralkyl of 1 to 4 carbon atoms and R.sub.9 and R.sub.10 are independently selected from hydrogen, hydroxy, methoxy, loweralkyl of 1 to 4 carbon atoms, or halo, or R.sub.9 and R.sub.10 can be taken together to form a methylenedioxy or ethylenedioxy bridge; or 1,4-benzodioxan of the formula ##STR5## wherein q is 1, 2 or 3, and R.sub.11 is hydrogen, methoxy, or halo; or R.sub.3 and R.sub.4 can be taken together to form a piperazino, piperidino or morpholino moiety; and the pharmaceutically acceptable salts thereof. Also disclosed are novel intermediates useful in the preparation of these compounds.

  本公开涉及由下式表示的1-氨基烷基-3,4-二氢萘烯衍生物，其中n为1或2；R、R.sub.1和R.sub.2分别选自氢、羟基、1至3个碳原子的低烷氧基、1至3个碳原子的低烯氧基、硫甲基、卤素，或下式中的其中一种：其中R.sub.5和R.sub.6分别选自氢、1至4个碳原子的低酰基或下式的磺酰基：其中R.sub.7为1至4个碳原子的低烷基；或R和R.sub.1，或R.sub.1和R.sub.2可结合形成亚甲二氧桥或乙烯二氧桥；但R、R.sub.1或R.sub.2中至少有一个必须为氢以外的其他基团；R.sub.3和R.sub.4分别选自氢、1至4个碳原子的低烷基、1至4个碳原子的卤素取代的低烷基、下式的芳基烷基：其中m为0、1或2，p为0或1，R.sub.8为氢或1至4个碳原子的低烷基，R.sub.9和R.sub.10分别选自氢、羟基、甲氧基、1至4个碳原子的低烷基或卤素，或R.sub.9和R.sub.10可结合形成亚甲二氧桥或乙烯二氧桥；或下式的1,4-苯二氧杂环己烷：其中q为1、2或3，R.sub.11为氢、甲氧基或卤素；或R.sub.3和R.sub.4可结合形成哌嗪基、哌啶基或吗啉基；以及其药用盐。还公开了用于制备这些化合物的新型中间体。
• Jouannetaud, Marie-Paule; Jacquesy, Jean-Claude; Karam, Omar, Bulletin de la Societe Chimique de France, 1994, vol. 131, # 3, p. 284 - 290
  作者：Jouannetaud, Marie-Paule、Jacquesy, Jean-Claude、Karam, Omar、Coustard, Jean-Marie、Ferron, Bruno

  DOI：——

  日期：——